SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 1/19/2017 10:28:43 PM - Followers: 701 - Board type: Free - Posts Today: 99

Cellceutix Corporation (CTIX)
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  [email protected]
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at 


Ongoing Human Trials:
Product Pipeline:


FDA Designations:

Upcoming Milestones:

Recent News and Press Releases:

Seeking Alpha focus articles on CTIX:

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
[email protected]

Share Structure:  See SEC filing link above for current share structure

Cellceutix IP - Patent Filings:



Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:  [email protected]

Following is a WEEKLY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/04/2017 03:58:28 PM
CTIX News: Current Report Filing (8-k) 11/15/2016 06:25:29 AM
CTIX News: Quarterly Report (10-q) 11/09/2016 06:06:41 AM
CTIX News: Amended Annual Report (10-k/a) 10/28/2016 05:02:25 PM
CTIX News: Current Report Filing (8-k) 09/15/2016 08:01:38 AM
#168566  Sticky Note We can fight back by filing a complaint sox040713 01/17/17 02:02:05 PM
#168245  Sticky Note About Kevetrin should be made sticky: Blue Fin 01/13/17 11:28:38 AM
#165552  Sticky Note B-UP Due Diligence sox040713 12/09/16 12:17:52 PM
#165491  Sticky Note New Oral Psoriasis Drug Tops Cellceutix Catalysts $CTIX http://www.seekingalpha. Matagordaville 12/08/16 04:55:12 PM
#165310  Sticky Note News: Cellceutix Phase 2 Trial Dose Escalates in BooDog 12/07/16 07:40:13 AM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#168917   No one could have anticipated the Mako/Rosen attack. NotAsBigKahuna 01/19/17 10:39:47 PM
#168916   Interesting. If I sold all my shares at septmike09 01/19/17 10:38:08 PM
#168914   I agree. And insider buys happen all noretreat 01/19/17 10:23:38 PM
#168913   Give me a break noretreat 01/19/17 10:21:47 PM
#168912   This is not "wishful" thinking! Thanks. DaubersUP 01/19/17 09:54:21 PM
#168911   My prediction for tomorrow is if we open septmike09 01/19/17 09:47:05 PM
#168910   Just turn it off. It's best. TheDane 01/19/17 09:42:44 PM
#168909   "You are Right!! Always!! loanranger 01/19/17 09:39:26 PM
#168908   Confidentiality Agreements: A Basis for Partnerships georgejjl 01/19/17 09:26:06 PM
#168907   I think there was one for the implant EasyRider 01/19/17 09:20:29 PM
#168906   Peer review process georgejjl 01/19/17 09:18:24 PM
#168905   The C word: Nov 15, 2016 was the Areader 01/19/17 09:15:41 PM
#168904   I don't know the answers. But as a Barron4664 01/19/17 09:13:59 PM
#168903   "why a year for peer review for a Areader 01/19/17 09:08:31 PM
#168902   "Focus on the trials, not whether a CEO loanranger 01/19/17 08:56:59 PM
#168901   Expect the CTIX share price to triple by georgejjl 01/19/17 08:51:05 PM
#168900   Confidence for who? The insecure shareholder? There are septmike09 01/19/17 08:30:56 PM
#168899   ...IF SA coordinates with authors...once approved, it is Justfactsmam 01/19/17 08:24:29 PM
#168898   "let them figure out whether or not it loanranger 01/19/17 08:18:21 PM
#168897   the business side of these endeavors are septmike09 01/19/17 08:12:30 PM
#168895   thanks govorchin 01/19/17 07:52:35 PM
#168894   i do not buy "it has always been govorchin 01/19/17 07:47:55 PM
#168893   DR. Reddy can't compete with BP. runninggirl2016 01/19/17 07:47:45 PM
#168892   Loanranger, One year ago I asked the exact same Barron4664 01/19/17 07:42:58 PM
#168891   XenoPort is not a good comp as it Waverunner1 01/19/17 07:39:50 PM
#168889   Unless the argument is being made that CTIX loanranger 01/19/17 07:39:42 PM
#168887   "I say negotiate for one drug and get F1ash 01/19/17 07:31:13 PM
#168886   The problem is 5 years is nothing for septmike09 01/19/17 06:54:43 PM
#168885   You must have read my haiku for Leo. Synagogue hopeful! scottsmith 01/19/17 06:51:28 PM
#168884   isn't that convenient? we have been hearing govorchin 01/19/17 06:47:23 PM
#168883   Let's go one step further...the only shares that ROMAD Diver 01/19/17 06:45:58 PM
#168882   CTIX has stated that they are in discussions JTORENCE 01/19/17 06:40:28 PM
#168881   Bingo! Aren't we lucky to have Sullivan at Ringrock 01/19/17 06:39:51 PM
#168879   A Non-disclosure agreement (NDA), also known as a sox040713 01/19/17 06:32:27 PM
#168878   FINRA short sales of CTIX AlanC 01/19/17 06:30:37 PM
#168877   Buy/partnership is a must this year. If not JTORENCE 01/19/17 06:30:16 PM
#168876   Yes, they have, and that is something I KarinCA 01/19/17 06:29:03 PM
#168875   I think they have been very open about things. noretreat 01/19/17 06:25:30 PM
#168874   sox mind sharing with us ,how your research JTORENCE 01/19/17 06:24:30 PM
#168873   72 days of Prurisol enrollment...Tic toc runninggirl2016 01/19/17 06:18:54 PM
#168872   If we initiate those 5 studies then runninggirl2016 01/19/17 06:16:54 PM
#168871   Wonder if any Big Pharma will be interested? runninggirl2016 01/19/17 06:15:31 PM
#168870   Insiders of Leo's ex-employer have been buying. Might sox040713 01/19/17 06:01:29 PM
#168869   PPS doesn’t tell the whole story. One needs sox040713 01/19/17 05:56:01 PM
#168868   I have seen insiders buy and the stock septmike09 01/19/17 05:53:34 PM
#168867   Whomever they are in discussions with for a KarinCA 01/19/17 05:33:58 PM
#168866   what are they holding? noretreat 01/19/17 05:32:09 PM
#168865   CTIX, Here's our take article... Not sure if Rdunn88 01/19/17 05:31:04 PM
#168864   I was under the impression that insiders can't KarinCA 01/19/17 05:23:38 PM
#168863   There are any number of reasons why insiders noretreat 01/19/17 05:20:07 PM